TOPAbout TaihoFinancial Highlights

Financial Highlights

Taiho Pharmaceutical Co., Ltd. Each Fiscal Year Ending March 31

Millions of yenThousands of
U.S. dollars

(Note 2)

Millions of yen 2012
3/13
2011
3/12
2010
3/11
2009
3/10
2008
3/09

(Note 1)

2012
3/13
For the Year:
Net sales ¥125,002 ¥124,312 ¥123,581 ¥120,716 ¥91,027 $1,329,817
Operating income 15,209 16,328 15,778 14,564 11,589 161,800
Net income 11,164 10,209 12,127 10,464 8,067 118,776
Research and development expenses 30,428 28,094 30,262 29,735 22,439 323,701
R&D ratio to net sales (%) 24.3% 22.6% 24.5% 24.6% 24.7% 24.3%
Capital expenditures 10,217 3,927 5,840 4,396 1,469 108,700
At Year-End:
Total assets ¥363,641 ¥359,792 ¥354,882 ¥346,619 ¥334,290 $3,868,530
Total shareholders' equity 330,764 324,005 319,333 313,019 306,271 3,518,767
Employees 2,521 2,557 2,622 2,643 2,513 2,521

Note1. Due to the change in reporting period, FY 2008 includes results of 9 months from July 2008 to March 2009

        2. U.S. dollar amounts are translated from yen, for convenience only, at the rate of •94=US$1, the approximate exchange rate at March 31, 2013


Top of Page